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In recent years endoscopically controlled laser-induced thermal therapy (LITT) has been
increasingly accepted as a minimally invasive method for palliation of advanced or recurrent
head and neck or gastrointestinal cancer. Previous studies have shown that adjuvant
chemotherapy can potentiate endoscopic laser thermal ablation ofobstructing tumors leading
to improved palliation in advanced cancer patients. Eight patients with recurrent head and
neck tumors volunteered to enroll as part ofan ongoing phase II LITT clinical trial, and also
elected to be treated with systemic chemotherapy (cisplatin, 80mg/m2) followed 24 h later by
palliative laser thermal ablation. Laser treatments were repeated in patients with residual
disease or recurrence for a total of27 LITT sessions. Four ofthe 8 patients treated with laser
thermal chemotherapy remained alive after a median follow-up of12 months. Ofthe 12 tumor
sites treated, complete responses were located in the oral cavity (3), oropharynx (1),
hypopharynx (1), maxillary sinus (1), and median survival for these patients was 9.5 months.
This initial experience with cisplatinum-based laser chemotherapy indicates both safety and
therapeutic potential for palliation of advanced head and neck cancer but this must be con-
firmed by longer follow-up in a larger cohort of patients.
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INTRODUCTION
Laser induced thermal therapy (LITT) using the
Nd:YAG laser via endoscopic fiberoptics has
been increasingly accepted as an effective palliative
method for tumor ablation [1-4]. LITT facilitated
by endoscopy is of great value for less invasive
palliation of advanced obstructing cancers of the
head and neck, as well as for the gastrointestinal
and bronchial tracts by endoscopic recanalization
[1,2,4]. High photo-thermal laser energy levels are
delivered to the area of maximum obstruction but
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lower levels to the tumor margins, which frequently
remain undertreated resulting in recurrences [1-4].
Despite well documented tumor responses and an
apparently increased patient survival after LITT,
the need for repeated palliative laser sessions sug-
gests that more effective treatment may be possible
by combined drug and laser therapy [5-11]. Cis-
platin in combination with other anticancer agents
has been successfully used together with Nd YAG
laser therapy for endoscopic palliative treatment of
advanced esophageal and gastric cancer [6-11] and
is a current clinical protocol as an alternative to
radiation therapy for treatment of retinoblastomas
as reported by several investigators [12-14]. The
rationale for combined laser and chemotherapy is
based on the observation that tumor recurrence
after LITT occurs at the margin and that drug
enhancement by hyperthermia at these sites could
eliminate or reduce this tumor regrowth [7,8].
PATIENTS AND METHODS
Based on reports that chemotherapy enhances
palliative endoscopic laser therapy in advanced
esophageal and gastric cases [6-11], the authors
began a pilot study from July 1994 to July 1998,
testing combined cisplatin and laser induced ther-
mal therapy in 8 patients with recurrent head and
neck tumors who were not candidates for conven-
tional surgery and radiation treatment. Treatments
were not limited to endoscopic laser ablation of
recurrent tumors in the oropharynx, larynx and
hypopharynx, but also included other tumor sites
such as the oral cavity, maxillary sinus, neck and
skin. The treatment schedule was divided into two
phases. An initial treatment phase occurred when
patients were administered cisplatin followed by
laser treatment with the intention of relieving
symptoms via drug enhanced ablation of recurrent
tumor. The follow-up phase occurred when the
patients returned for maintenance laser therapy in
cases where post-operative tumor regrowth was
visible or microscopic biopsies identified positive
tumor margins.
For initial treatment each patient was admitted
on the day before surgery and administered cis-
platin, 80mg/m
2 intravenously over h and sched-
uled for LITT tumor ablation the next day. All
subjects were examined by flexible fibroscopy and
radiological exam to assist in adequate tumor
staging and to evaluate spread of disease. These
patients were treated by Nd:YAG laser ablation as
part of a Phase II study that evolved in a step-wise
fashion over the last decade [15]. Patients were
excluded if the Karnofsky performance status was
less than 70% or in cases with tumor immediately
adjacent to the carotid artery, esophagus or trachea.
Tumor volume, was measured using the formula
(L W H)/2, where L is the greatest diameter,
W is the greatest perpendicular width, and H is the
greatest depth or height. Tumor volume ranged
from 1.5 to 105 cm3. Patient’s medical records and
follow-up were available to accurately assess treat-
ment area, tumor size, and outcome in recurrent
and/or metastatic unresectable tumors that were
unresponsive to previous treatment. Age distribu-
tion of the reviewed cases ranged from 50 to 85
years, with a peak incidence in the seventh decade.
The 6 men and 2 women each presented with one or
2 tumors and all had a past history of cigarette
smoking. All patients had a diagnosis of squamous
cell carcinoma confirmed by biopsies.
All LITT procedures were performed in the
operating room, usually on an outpatient basis.
After obtaining appropriate informed consent, the
patients were placed on continuous cardiac and
pulse oximetry monitoring and then heavily sedated
in 37% of cases, or placed under general anesthesia
(63%). Initially, biopsies were performed at the
tumor margins using a clockwise orientation before
starting laser therapy. An SLT Nd:YAG laser
(1064 nm, SLT Co. Oaks, PA) was employed for
all tumor treatments, with the intention’to thermally
ablate tumor tissue. The free beam laser energy at
continuous mode (50W) was delivered via fiber-
optics for a total of 11 endoscopic procedures, or
through a handpiece in 16 procedures. Endoscopic
procedures were performed in 3 patients by suspen-
sion microlaryngoscopy for ablation of tumors inCISPLATIN AND LASER THERMAL THERAPY 135
the larynx, pharynx and oropharynx. The laser
application was performed initially at 5mm beyond
the tumor margins in a centripetal configuration
directing the light beam perpendicularly from above
with the tip of the handpiece 5mm over the target
tissue. The beam was maintained for 5-7 s on each
target spot to achieve an energy density of 1600 to
2200 J/cm
2 per application. After carbonization of
the tumor, debris was removed by suction. Follow-
ing completion of debulking, the tumor bed with
margins of 10mm was treated again with the laser in
the same fashion using a similar energy density. This
produced a deeper layer ofphotoablation and better
tumor eradication as well as photocoagulation of
smaller vessels.
All patients with recurrent neck tumors needed
ultrasound assistance (UTZ) to facilitate localiza-
tion ofthe tumor in relation to the carotid artery and
ensure that laser energy deposition remained away
from vital structures, as described previously [15].
After treatment all patients were followed by repeat
visits to the outpatient clinic every 3-5 weeks where
they were examined clinically and performance
status was reassessed and recorded. Each patient’s
overall outcome after therapy was recorded as
complete, partial or no response, based on duration
of follow-up. Complete response (CR) was defined
as no visible tumor; partial response (PR) exhibited
a decreased initial tumorvolume of > 50% followed
by delayed regrowth; no response (NR) was defined
by greater than 50% of pre-therapy tumor size or
rapid tumor regrowth after treatment.
RESULTS
Twelve recurrent tumors in 8 patients were treated
by combined laser and cisplatin therapy, with
tumors occurring in the oral cavity (3), skin (2),
neck (2), oropharynx, hypopharynx, larynx, nose,
and maxillary sinus. Overall, pain was the major
complaint (4 patients), while other symptoms
included dysphagia, dyspnea, bleeding, and diffi-
culties in chewing. Table I gives a summary of the
patients’ profile. Twenty-seven laser procedures
were performed: 8 were initial treatment phase using
cisplatin as a booster for laser therapy and 19 were
repeated procedures during follow-up phase. The
mean energy required to produce remission was
22.5kJ (range 4.8-54kJ) in the initial treatment
phase, and 9.3 kJ (range 3.6-21.5 kJ) in the follow-
up phase. Average time interval between treatments
was 4.8 weeks. Twenty of27 LITT procedures were
performed as a same-day surgery (74%) and 7
(26%) required one day hospitalization. Average
anesthesia time for these procedures was 63 min
which illustrates the speed and simplicity of com-
bined LITT as an alternative to surgical resection.
Laser and cisplatin treatments led to CR in 6 of 12
tumors treated. Five patients had improvement
and/or resolution of symptoms after one to 6
sessions (average of 3.3 procedures per patient).
Detailed results of these treatments are included in
Table II.
A 52-year-old male (patient #2) was unresponsive
to conventional treatment. He presented with
TABLE Clinical profile of patients selected for Nd:YAG laser and cisplatin combined therapy
Patient Sex/age Previous Reason for SCCA Histol. Treatment
no. treatment treatment differentiation site
Tumors (n) Tumor vol.
range cm
m/60 Surg/rad/chemo Unresectable
2 m/52 Surg/rad/chemo Unresectable
3 m/60 Rad/chemo Refused surg/rad
4 m/69 Rad Refused surg/rad
5 f/85 Surg/rad/chemo Not surg. candidate
6 m/50 Surg/rad/chemo Unresectable
7 m/70 Surg/rad/chemo Unresectable
8 f/75 Surg/rad/chemo Not surg. candidate
Poor Oropharynx 50
Poor Nasal/oral cav/skin 4 1.5-3.8
Poor Floor ofMouth 32
Moderate Larynx 5.4
Moderate Hypopharynx 2.4
Poor Oral Cavity/neck 2 3.2-24
Poor Neck 105
Poor Maxillary sinus 5.1136 M.B. PAIVA et al.
TABLE II Outcome and follow-up after Nd’YAG laser treatment
Patient Nd" YAG
no. sessions
Sessions for Survival Tumor
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recurrent rapidly growing facial subcutaneous
(2 tumors), palatal and posterior septal poorly
differentiated squamous cell tumors. Tumor abla-
tion was achieved after initial combined therapy,
but rapid regrowth occurred after every laser
application and further treatment was stopped after
4 sessions. Patients #6 and #7 had reasonable
palliation with some reduction in tumor growth
rate but eventually expired due to further progres-
sion of the disease (5 and 8 months survival
respectively). Targeting neck tumors with the
external laser technique was difficult in these 2
patients with advanced neck disease due to deep
tumor invasion around nervous plexi and vessels.
Both patients had an initial combined cisplatin and
LITT ablation under ultrasound (UTZ) guidance
and a second LITT without cisplatin, also under
UTZ guidance during the follow-up phase. Treat-
ment of neck lesions was challenging because these
tumors frequently impinge on vital structures after
recurrence following failure of wide surgical resec-
tion. Patient #7 had extensive recurrence in the neck
that encroached around the right common carotid
artery with a partial response to initial laser and
cisplatin therapy followed by 2 LITT sessions
without chemotherapy, as seen in Fig. 1.
Four patients showed CR after combined treat-
ment. Patient # 1, a 60-year-old male presented with
a rapidly growing left lateral pharyngeal wall and
base of tongue poorly differentiated squamous cell
carcinoma (50 cm3) that failed previous surgery and
radiation. The patient showed a dramatic tumor
reduction and negative repeat biopsies after first
laser and cisplatin treatment. Unfortunately, the
FIGURE (A) Preoperative view of a right neck metastatic
squamous cell cancer (patient #7), and (B) view 2 weeks after
third treatment with the Nd’YAG laser showing a PR to
treatment.
patient had a stroke 5.5 months after initial
treatment and could not be followed for long term
response. Another patient (#4) also was not avail-
able for extended follow-up because he elected to
discontinue further treatment. This 69-year-old
male presented with a recurrent T4 laryngeal
carcinoma, which had failed previous radiationCISPLATIN AND LASER THERMAL THERAPY 137
therapy. He refused a total laryngectomy, but
agreed to undergo cisplatin and LITT therapy via
laryngoscopy for treatment of the carcinoma. This
patient underwent other 5 LITT treatments, with
negative tumor biopsies after 4 treatments. Four-
teen months after first treatment, the patient had
poor voice function and was breathing without a
tracheotomy, but refused to undergo routine serial
sessions of suspension laser microlaryngoscopy for
biopsies during the follow-up phase of the study.
The patient subsequently was reported to have
undergone a total laryngectomy. Patient #3 who
presented with aT4NOM0 squamous cell carcinoma
of the floor of mouth had an apparent curative
response after a single session ofcombined laser and
cisplatin therapy with no evidence of tumor recur-
rence during 4 years follow-up (Fig. 2). Biopsies
performed at 2.5 years after initial treatment were
negative and this patient remains active with a good
quality of life.
Minor side-effects of the initial treatment phase
with cisplatin and laser were common to most ofthe
patients including a sensation of weakness with no
objective findings in 4 patients and nausea with
vomiting in 2 patients. These symptoms spontane-
ously resolved within a few days except in patient
# 8 who responded with mild alopecia (grade 2NIH
toxicity score). No intra-operative adverse medical
reactions were seen when Nd:YAG laser LITT was
administered after systemic cisplatin administra-
tion. This combined treatment was well tolerated in
7 patients at the selected laser power and drug levels,
causing no discernible adverse effects to overlaying
soft tissue or adjacent structures. As a palliative
form of therapy, most laser treatments were per-
formed on an outpatient basis (74%) and median
survival in this series of patients was 9.5 months.
The survival curve for the entire study is shown
in Fig. 3.
DISCUSSION
Local recurrence after endoscopic laser thermal pal-
liation is frequently related to residual disease from
FIGURE 2 (A) Preoperative view of an extensive squamous
cell cancer of the floor of mouth (patient #3), and (B) view
immediately after treatment with cisplatin and Nd:YAG laser;
and (C) post-operative result after 3 years, showing a well
healed defect covered by a skin flap.
untreated areas in the tumor margins. Repeated
laser thermal ablation sessions are usually needed
for effective palliation to induce eventually tumor
remission using LITT. In an effort to improve
palliative endoscopic laser thermal ablation of
advanced malignancies, several investigators have
tested combined chemotherapy prior to tumor138 M.B. PAIVA et al.
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FIGURE 3 Kaplan Meier survival curve of patients mea-
sured in months after the initial treatment.
ablation. Semler et al. [6] first reported a signifi-
cant improvement of quality of life in 21 of 24
patients with advanced gastrointestinal tumors
when systemic chemotherapy was administered
before intraluminal endoscopic Nd:YAG laser
thermal ablation. Mache [7] confirmed survival
benefits of this alternative combined treatment
for palliation of advanced upper gastrointestinal
tumors. Firusian [8] previously reported that 13
patients with stenotic upper gastrointestinal cancer
treated by endoscopic palliative laser ablation and
cisplatin in combination with other anticancer
drugs, responded favorably after combined laser
chemotherapy compared to laser alone as a pal-
liative approach for advanced malignant disease. In
most of the 13 patients combined therapy led to
immediate patency of the upper alimentary tract
and 8 months median survival in the cohort studied.
The author also found that local laser thermal
effects were enhanced by systemic chemotherapy
leading to additional ablation of malignant cells
down to 7-8mm depth compared to 4mm for laser
alone treatment. Combined drug and laser therapy
was more effective in preventing rapid cell prolifera-
tion at the tumor margins [8].
Cisplatin combined with other chemotherapy
agents in different regimens has been the drug of
choice in several laser endoscopic palliative studies
[9-11]. Mason [11] reported a study on endoscopic
Nd:YAG laser ablation comparing treatment
alone versus laser plus systemic chemotherapy in
patients with inoperable esophageal cancer and
observed that combined therapy produced a
response in ’two-thirds of cases with relief of
dysphagia and increase in survival. The author also
compared 2 groups receiving combined laser and
chemotherapy treatments FA/5-FU (Folinic acid
and Fluoracil, i.v.), and ECF (Epirubicin, cisplatin
and 5-Fluoracil, i.v.). No response was seen in
patients treated with FA/5-FU, compared to a
61% response in patients treated by ECF with a
significant reduction in need for additional laser
therapy to maintain swallowing [11].
Accumulating evidence indicates that heat induc-
tion causes ultrastructural changes in tumor cell
membranes leading to increased membrane trans-
port of drugs and altered cellular metabolism
[16,17]. Higher CDDP uptake after heating also
enhances cytotoxicity in proliferating cancer cells
and stimulates protein kinases to induce tumor
apoptosis [18]. Studies of CDDP binding to DNA
have shown that hyperthermia induces more DNA
adducts, contributes to increased tumor growth
delay, and amplifies interstrand crosslinks by
cisplatinum [19-23]. Together, these results provide
strong evidence that synergistic effects of heat
and cisplatinum are likely to improve therapeutic
response of recurrent head and neck tumors fol-
lowing combined drug and laser treatment.
A drug implant of cisplatinum with collagen as
a protein matrix and epinephrine, (CDDP/gel, or
IntradoseTM) allows higher intratumor drug levels
to be maintained for nearly 24 h [24]. This slow
release drug gel has been found to be safe and
feasible for palliation of esophageal as well as head
and neck and liver tumors [24]. The CDDP drug
implant also may provide an alternative combined
technique with LITT for more effective therapy
without systemic drug toxicity. Combining CDDP/
gel with LITT in a human squamous cell carcinoma
tumor transplant model resulted in significant ther-
apeutic improvement compared to systemic or
intratumor injection of cisplatin in several recent
pre-clinical studies [5,25,26]. Currently, patients
with advanced head and neck cancer are palliated
atUCLA either by laser ablation in a phase II study
or by intralesional cisplatin injection (CDDP/
epi-gel, phase III study) with clear evidence of
tumor regression in a number of patients, but with
eventual recurrence in the majority of cases [15,24].CISPLATIN AND LASER THERMAL THERAPY 139
An obvious next step is to combine intratumor
cisplatin injections with interstitial Nd:YAG laser
therapy for cancer treatment [5,26].
The options for active palliation of local symp-
toms in inoperable patients are usually very limited
[2,15]. Although the current study was based on a
small number ofpatients with heterogeneous tumor
size and locations, the benefits ofcombined therapy
appeared to be substantial in three cases. Four ofthe
8 patients remain alive, 3 in tumor remission with a
current median follow-up of 12 months. This favor-
able outcome is possibly related to adequate cis-
platin perfusion of the margin tumor regions 24 h
after systemic administration of chemotherapy
combined with LITT [8,11,14]. A total of4 patients
expired after combined laser and chemotherapy
(survival range of 4-8 months). Three had disease
progression and one died of intercurrent illness
while in tumor remission. This pilot clinical study
indicates that combining laser ablation and chemo-
therapy may become an effective method provid-
ing palliative treatment for some patients with
advanced head and neck tumors. However, longer
follow-up in a larger cohort of patients and ran-
domized clinical trials are needed to fully validate
LITT and chemotherapy as a less invasive combined
treatment option for palliation of head and neck
cancer.
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